跳至主要内容
临床试验/NCT02161315
NCT02161315Unknown不适用

A Randomized Study of Steroid Aromatase Inhibitors Versus Progestogens for Non-Steroid Aromatase Inhibitor-resistanced Late Stage Breast Cancer

Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2014年4月最近更新:
适应症

试验速览

阶段
不适用
入组人数
80
试验地点
1
主要终点
RECIST 1.1

研究概览

简要总结

Steroid Aromatase Inhibitors and Non-Steroid Aromatase Inhibitors in Late Stage Breast Cancer is the recommended scheme in National Comprehensive Cancer Network (NCCN) guideline. In the past controlled clinical trials with small sample.

详细描述

A Randomized Study of Steroid Aromatase Inhibitors Versus Progestogens for Non-Steroid Aromatase Inhibitor-resistanced Late Stage Breast Cancer.The primary endpoints of the study is progression free survival (PFS). The secondary endpoints are overall response rate (ORR), overall survival (OS) and safety.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

性别
Female
接受健康志愿者

入选标准

  • Patients must be the postmenopausal women
  • Patients must be diagnosed with advanced breast cancer by imageology,cytology or histopathology
  • Immunohistochemistry shows ER and/or PR positive
  • Patients ECOG score must be 0-2
  • Drug resistant about Non-Steroid Aromatase Inhibitors

排除标准

  • Not suitable for endocrine therapy
  • Have receive the standard Steroid Aromatase Inhibitors treatment
  • Severe hepatic dysfunction

结局指标

主要结局

RECIST 1.1

时间窗: -7 days

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验